Biotechnology - Pharmaceutical, Metabolics

Filter

Current filters:

PharmaceuticalMetabolics

Popular Filters

AstraZeneca unit links with NGM Biopharma on diabetes and obesity research

17-06-2013

Anglo-Swedish drug major AstraZeneca's (LSE: AZN) US biologics R&D subsidiary MedImmune has entered into…

AstraZenecaBiotechnologyDiabetesLicensingMedImmuneMetabolicsNGM BiopharmaceuticalsPharmaceuticalResearch

OPKO Health to acquire PROLOR Biotech in $480 million stock deal

25-04-2013

Continuing on its acquisitive path, US drugmaker OPKO Health (NYSE: OPK) has signed a definitive agreement…

BiotechnologyMergers & AcquisitionsMetabolicsOPKO HealthPharmaceuticalPROLOR Biotech

AstraZeneca acquires AlphaCore; Merck Serono links with BioMed X

03-04-2013

In line with its stated policy of targeted acquisitions, Anglo-Swedish drug major AstraZeneca (LSE: AZN)…

AlphaCore PharmaAstraZenecaBiotechnologyCardio-vascularMerck KGaAMerck SeronoMergers & AcquisitionsMetabolicsPharmaceuticalResearch

FDA advisory gives thumbs down for Zogenix' Zohydro for chronic pain; EU label extension for Genzyme's Thyrogen

10-12-2012

Shares of USA-based Zogenix (Nasdaq: ZGNX) plummeted 33.5% to $1.57 in after-hours trading on Friday…

BiotechnologyEuropeGenzymeMetabolicsNeurologicalNorth AmericaPharmaceuticalRegulationSanofiThyrogenZogenixZohydro

Vivus plummets as early sales of obesity drug Qsymia disappoint

08-11-2012

US biopharma company Vivus (Nasdaq: VVUS) saw its shares plunge 24% to $11.38, after reporting third-quarter…

BiotechnologyFinancialMetabolicsPharmaceutical

AstraZeneca aligns with Regulus for microRNA therapeutics

16-08-2012

Anglo-Swedish drug major AstraZeneca (LSE: AZN) and US biotech firm Regulus Therapeutics have signed…

AstraZenecaBiotechnologyCardio-vascularLicensingMetabolicsPharmaceuticalRegulus Therapeutics

Low-dose Ampyra fails in multiple sclerosis study, says Acorda

15-08-2012

USA-based biotech firm Acorda Therapeutics (Nasdaq: ACOR) has announced top line results from a post-marketing…

Acorda TherapeuticsAmpyraBiotechnologyMetabolicsNeurologicalPharmaceuticalResearch

Arena Pharma gets positive FDA panel vote for obesity drug; prophylactic Truvada backed

11-05-2012

USA-based Arena Pharmaceuticals (Nasdaq: ARNA) and Japanese licensing partner Eisai (TYO: 4523) got a…

Anti-viralsArena PharmaceuticalsBiotechnologyEisaiGilead ScienceslorcaserinLorquessMetabolicsNorth AmericaPharmaceuticalRegulationTruvada

EMA turns positive on orlistat and aprotinin; CHMP backs Pixuvri

20-02-2012

Finalizing its review on orlistat-containing medicines and the possible risk of severe liver injuries,…

AlliBayerBiotechnologyCardio-vascularCell TherapeuticsEuropeGlaxoSmithKlineMetabolicsOncologyorlistatPharmaceuticalPixuvriRegulationRocheTrasylolXenical

Company Spotlight

ImmunoGen

ImmunoGen

Back to top